The TRA2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction) trial evaluated vorapaxar, a competitive and selective antagonist of PAR-1, on top of standard antithrombotic therapy as secondary prevention for patients with established atherosclerosis (history of MI, stroke or PAD) [29]. This evidence concerns the gene F2R and Stroke.